Nuvalent Investor Relations Material
Latest events
Q1 2025
7 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Nuvalent Inc
Access all reports
Nuvalent, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients. The company specializes in the creation of small molecule inhibitors that are designed to target specific kinases with high precision. Its leading product candidates include NVL-520, which targets ROS1-positive non-small cell lung cancer, and NVL-655, aimed at addressing ALK-positive cancers. Both candidates are designed to overcome resistance and minimize adverse events associated with existing treatments. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Latest articles
)
Luca de Meo: Succeeding Pinault as the New CEO of Kering
Luca de Meo's leap from auto to luxury marks a bold new chapter as he becomes the first non-Pinault CEO to lead the Kering empire.
16 Jun 2025
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
Ticker symbol
NUVL
Country
🇺🇸 United States